Last reviewed · How we verify

Fentanyl and Propofol

Jiangsu Hengrui Pharmaceutical Co., Ltd. · FDA-approved active Small molecule Under review Quality 0/100

Fentanyl and Propofol is a Opioid agonist + sedative-hypnotic combination Small molecule drug developed by Jiangsu Hengrui Pharmaceutical Co., Ltd.. It is currently FDA-approved for Induction and maintenance of general anesthesia, Sedation in intensive care units, Procedural sedation.

Fentanyl is an opioid agonist that binds mu opioid receptors to provide analgesia, while propofol is a sedative-hypnotic that enhances GABA inhibitory neurotransmission to induce unconsciousness.

Propofol is a small molecule that acts as a positive allosteric modulator of the GABA-A receptor, an anion channel. It is used in general anesthesia and has been studied in various clinical trials for conditions such as perioperative pain management and fluid management during elective spine surgeries. Fentanyl is not mentioned in the provided facts, but Propofol is.

At a glance

Generic nameFentanyl and Propofol
SponsorJiangsu Hengrui Pharmaceutical Co., Ltd.
Drug classOpioid agonist + sedative-hypnotic combination
TargetMu opioid receptor (fentanyl); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

This is a combination product used for anesthesia and sedation. Fentanyl acts as a potent mu opioid receptor agonist, providing rapid-onset analgesia and contributing to anesthetic depth. Propofol is an intravenous sedative-hypnotic that potentiates GABA-A receptor signaling, producing sedation, hypnosis, and amnesia. Together, they provide balanced anesthesia with analgesia and hypnosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fentanyl and Propofol

What is Fentanyl and Propofol?

Fentanyl and Propofol is a Opioid agonist + sedative-hypnotic combination drug developed by Jiangsu Hengrui Pharmaceutical Co., Ltd., indicated for Induction and maintenance of general anesthesia, Sedation in intensive care units, Procedural sedation.

How does Fentanyl and Propofol work?

Fentanyl is an opioid agonist that binds mu opioid receptors to provide analgesia, while propofol is a sedative-hypnotic that enhances GABA inhibitory neurotransmission to induce unconsciousness.

What is Fentanyl and Propofol used for?

Fentanyl and Propofol is indicated for Induction and maintenance of general anesthesia, Sedation in intensive care units, Procedural sedation.

Who makes Fentanyl and Propofol?

Fentanyl and Propofol is developed and marketed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (see full Jiangsu Hengrui Pharmaceutical Co., Ltd. pipeline at /company/jiangsu-hengrui-pharmaceutical-co-ltd).

What drug class is Fentanyl and Propofol in?

Fentanyl and Propofol belongs to the Opioid agonist + sedative-hypnotic combination class. See all Opioid agonist + sedative-hypnotic combination drugs at /class/opioid-agonist-sedative-hypnotic-combination.

What development phase is Fentanyl and Propofol in?

Fentanyl and Propofol is FDA-approved (marketed).

What are the side effects of Fentanyl and Propofol?

Common side effects of Fentanyl and Propofol include Respiratory depression, Hypotension, Bradycardia, Injection site pain, Nausea and vomiting, Apnea.

What does Fentanyl and Propofol target?

Fentanyl and Propofol targets Mu opioid receptor (fentanyl); GABA-A receptor (propofol) and is a Opioid agonist + sedative-hypnotic combination.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing